[{"data":1,"prerenderedAt":233},["ShallowReactive",2],{"drug-ticagrelor":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":44,"contraindications":119,"warnings":129,"renal":137,"monitoring":138,"interactions":139,"review":140,"examples":143,"atc":157,"iran":159,"links":175,"populations":192,"usApproval":228},"ticagrelor",1,{"fa":7,"en":8},"تیکاگرلور","Ticagrelor","blood",{"fa":11,"en":12},"مهارکننده P2Y12 (ضدپلاکت)","P2Y12 inhibitor (antiplatelet)",[14],{"name":15,"market":16},"Brilinta","US",[18,19,20,7],"brilinta","brilique","بریلینتا",[22,36],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-60","tablet","oral","60 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},60,"mg",false,[16],[33],{"source":34,"section":35},"fda-brilinta","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":41,"refs":42},"tab-90","90 mg tablet",{"amount":40,"unit":29,"perUnit":24,"scored":30},90,[16],[43],{"source":34,"section":35},[45,63,84,97],{"id":46,"disease":47,"label":48,"population":51,"type":55,"unit":29,"dose":56,"refs":58,"durationDays":61,"allowedFormulations":62},"acs-load","acute-coronary-syndrome",{"fa":49,"en":50},"ACS — دوز بارگذاری ۱۸۰ mg","ACS — 180 mg loading dose",{"minAge":52},{"value":53,"unit":54},18,"year","fixed",{"perDose":57,"dosesPerDay":5},180,[59],{"source":34,"section":60},"2.2",{"min":5,"max":5},[37],{"id":64,"disease":47,"label":65,"population":68,"type":55,"unit":29,"dose":70,"refs":72,"allowedFormulations":74,"notes":75},"acs",{"fa":66,"en":67},"ACS یا سابقه MI — ۹۰ mg دو بار در روز (سال اول)، سپس ۶۰ mg دو بار","ACS or prior MI — 90 mg twice daily (first year), then 60 mg twice daily",{"minAge":69},{"value":53,"unit":54},{"perDose":40,"dosesPerDay":71},2,[73],{"source":34,"section":60},[37],[76],{"text":77,"refs":80},{"fa":78,"en":79},"اولین دوز نگهدارنده ۶ تا ۱۲ ساعت پس از بارگذاری. همراه آسپرین ۷۵ تا ۱۰۰ mg روزانه؛ آسپرین بیشتر نه.","First maintenance dose 6–12 h after loading. With aspirin 75–100 mg daily; avoid higher aspirin doses.",[81,82],{"source":34,"section":60},{"source":34,"section":83},"2.1",{"id":85,"disease":86,"label":87,"population":90,"type":55,"unit":29,"dose":92,"refs":93,"allowedFormulations":96},"cad","atherothrombotic-prevention",{"fa":88,"en":89},"بیماری عروق کرونر بدون سکته یا MI قبلی — ۶۰ mg دو بار در روز","CAD without prior stroke or MI — 60 mg twice daily",{"minAge":91},{"value":53,"unit":54},{"perDose":28,"dosesPerDay":71},[94],{"source":34,"section":95},"2.3",[23],{"id":98,"disease":99,"label":100,"population":103,"type":55,"unit":29,"dose":105,"refs":106,"durationDays":109,"allowedFormulations":111,"notes":112},"stroke","stroke-tia",{"fa":101,"en":102},"سکته ایسکمیک خفیف یا TIA — بارگذاری ۱۸۰ mg سپس ۹۰ mg دو بار تا ۳۰ روز","Minor ischaemic stroke or TIA — 180 mg load then 90 mg twice daily up to 30 days",{"minAge":104},{"value":53,"unit":54},{"perDose":40,"dosesPerDay":71},[107],{"source":34,"section":108},"2.4",{"min":110,"max":110},30,[37],[113],{"text":114,"refs":117},{"fa":115,"en":116},"همراه آسپرین بارگذاری ۳۰۰ تا ۳۲۵ mg و سپس ۷۵ تا ۱۰۰ mg روزانه.","With an aspirin load of 300–325 mg then 75–100 mg daily.",[118],{"source":34,"section":108},[120],{"id":121,"severity":122,"text":123,"refs":126},"ci","block",{"fa":124,"en":125},"سابقه خونریزی داخل جمجمه؛ خونریزی پاتولوژیک فعال؛ حساسیت.","History of intracranial haemorrhage; active pathological bleeding; hypersensitivity.",[127],{"source":34,"section":128},"4",[130],{"text":131,"refs":134},{"fa":132,"en":133},"هشدار جعبه‌ای: خطر خونریزی جدی و گاهی کشنده؛ پیش از CABG فوری شروع نشود؛ قطع زودهنگام خطر حوادث قلبی را بالا می‌برد.","Boxed warning: significant, sometimes fatal bleeding; do not start before urgent CABG; premature discontinuation increases cardiovascular events.",[135],{"source":34,"section":136},"Boxed Warning",[],[],[],{"status":141,"reviewer":142,"date":142},"unverified",null,[144,148,151,154],{"regimen":46,"formulation":37,"input":145,"expect":147},{"ageYears":28,"weightKg":146},80,{"perDose":57,"tabletsPerDoseRounded":71},{"regimen":64,"formulation":37,"input":149,"expect":150},{"ageYears":28,"weightKg":146},{"perDose":40,"tabletsPerDoseRounded":5},{"regimen":85,"formulation":23,"input":152,"expect":153},{"ageYears":28,"weightKg":146},{"perDose":28,"tabletsPerDoseRounded":5},{"regimen":98,"formulation":37,"input":155,"expect":156},{"ageYears":28,"weightKg":146},{"perDose":40,"tabletsPerDoseRounded":5},[158],"B01AC24",{"status":160,"forms":161,"refs":170},"registered",[162,166],{"code":163,"en":164,"fa":165},"18002","TICAGRELOR 90 MG TAB.","قرص تیکاگرلور ۹۰ میلی‌گرم .",{"code":167,"en":168,"fa":169},"52087","TICAGRELOR 60 MG TAB","قرص تیکاگرلور ۶۰ میلی‌گرم",[171],{"source":172,"section":173,"url":174},"darooyab-generic","G-4697\u002FTicagrelor","https:\u002F\u002Fwww.darooyab.ir\u002FG-4697\u002FTicagrelor",[176,180,184,187,190],{"kind":177,"url":178,"label":179},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022433","NDA022433",{"kind":181,"url":182,"label":183},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8","FDA Brilinta",{"kind":185,"url":186,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa611050.html",{"kind":188,"url":189,"label":158},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AC24",{"kind":191,"url":174,"label":8},"darooyab",{"pregnancy":193,"lactation":202,"pediatric":211,"geriatric":219},{"level":194,"text":195,"quote":198,"refs":199},"caution",{"fa":196,"en":197},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data from case reports with BRILINTA use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.",[200],{"source":34,"section":201},"8.1",{"level":203,"text":204,"quote":207,"refs":208},"avoid",{"fa":205,"en":206},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Breastfeeding is not recommended during treatment with BRILINTA.",[209],{"source":34,"section":210},"8.2",{"level":194,"text":212,"quote":215,"refs":216},{"fa":213,"en":214},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of BRILINTA have not been established in pediatric patients.",[217],{"source":34,"section":218},"8.4",{"level":220,"text":221,"quote":224,"refs":225},"ok",{"fa":222,"en":223},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between elderly and younger patients.",[226],{"source":34,"section":227},"8.5",{"kind":229,"refs":230,"id":179},"NDA",[231],{"source":34,"section":232},"SPL approval \u002F marketing category",1792111469736]